New Risk • Jun 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (AU$4.3m revenue, or US$2.9m). Market cap is less than US$100m (AU$64.1m market cap, or US$44.3m). Announcement • Jun 11
Prescient Therapeutics Limited Announces Chief Medical Officer Changes Prescient Therapeutics Limited announced the appointment of Dr Rosalind Wilson as Chief Medical Officer (CMO) effective 13 July 2026. Dr Wilson is a highly accomplished pharmaceutical and biotechnology executive with more than 30 years' experience spanning clinical development, regulatory strategy and executive leadership. Her appointment further strengthens Prescient's leadership team as the Company advances its pipeline through key stages of clinical development. The Company's current CMO, Dr Marissa Lim, has decided to step-back from full-time employment and move into semi-retirement, following a significant contribution to the progression of Prescient's clinical programs. Dr Wilson has held senior global leadership roles including Global Head of Drug Development at Telix Pharmaceuticals, CEO of ASX-listed Factor Therapeutics, and has previously served as Chief Medical Officer for oncology-focused biotechnology companies. Earlier in her career, she led the global development and launch strategy for pertuzumab (Perjeta) at Roche, contributing to accelerating approval timelines and landmark regulatory precedents in breast cancer. Her experience spans the full drug development continuum - from Phase 1 studies through to regulatory submission and commercial launch - across multiple oncology indications. As CMO, Dr Wilson will lead Prescient's clinical development strategy and execution, including advancement of PTX-100 in its Phase 2 CTCL study and progression of the broader pipeline. New Risk • May 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (AU$4.3m revenue, or US$3.0m). Market cap is less than US$100m (AU$86.2m market cap, or US$61.5m). Announcement • Sep 12
Prescient Therapeutics Limited, Annual General Meeting, Oct 14, 2025 Prescient Therapeutics Limited, Annual General Meeting, Oct 14, 2025. Location: at level 33, 477 collins street, melbourne vic 3000 Australia New Risk • Aug 24
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (29% increase in shares outstanding). Revenue is less than US$5m (AU$4.6m revenue, or US$3.0m). Market cap is less than US$100m (AU$44.7m market cap, or US$29.0m). Announcement • Jul 31
Prescient Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.9785 million. Prescient Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.9785 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 74,462,500
Price\Range: AUD 0.04
Discount Per Security: AUD 0.0024
Transaction Features: Subsequent Direct Listing Announcement • Jul 03
Prescient Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 7 million. Prescient Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 7 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 175,000,000
Price\Range: AUD 0.04
Discount Per Security: AUD 0.0024 Announcement • Apr 10
Prescient Therapeutics Limited Appoints Melanie Farris as Independent Non-Executive Director and Serve as Chair of the Audit and Risk Committee Prescient Therapeutics Limited announced the appointment of Melanie Farris to the Board as independent Non-Executive Director. Ms Farris brings extensive senior executive and board-level experience with prior appointments including Non-Executive Director and Company Secretary at Factor Therapeutics Limited; Non-Executive Director, Chief Financial Officer and Company Secretary at Invion Limited; and Chair of the Board of Directors of Synapse Australia Limited. Most recently with Telix Pharmaceuticals Limited, Melanie's positions included Senior Vice President Global Governance Risk and Compliance, Chief Governance and Risk Officer and Group Company Secretary where she had responsibility for governance, risk, internal audit and sustainability frameworks, operations and compliance. Prior to her career in life sciences, Melanie was COO of the UK's FourFour Promotions Limited and Development Executive for The Prince's Foundation. Ms Farris holds a Bachelor of Communication (Public Relations) and a Graduate Diploma in Applied Corporate Governance. She is a Fellow of the Governance Institute of Australia, a Fellow of the Chartered Governance Institute (UK) and a Graduate of the Australian Institute of Company Directors. Ms Farris will serve as Chair of the Audit and Risk Committee. Announcement • Mar 26
Prescient Therapeutics Limited Opens First Clinical Site for PTX-100 Phase 2a Study Prescient Therapeutics Limited announced that the first Site Initiation Visit (SIV) of its Phase 2a clinical study of PTX-100 has been completed. The Phase 2a clinical study will evaluate two dosage levels of PTX-100 on an open-label basis in approximately 40 patients with relapsed/refractory (r/r) Cutaneous T Cell Lymphoma (CTCL). The primary endpoint is efficacy and the secondary endpoints are several including safety. This marks a significant milestone in the progress of the Phase 2a study for PTX-100 for patients suffering CTCL. It is the first of multiple sites that will be initiated in Australia, the USA and Europe. Announcement • Mar 25
Prescient Therapeutics Limited Announces Change of Chief Medical Officer Prescient Therapeutics Limited announced the appointment of Dr. Marissa Lim as Chief Medical Officer (CMO), effective 24th March 2025. Dr. Lim will take over from current CMO, Dr. Terrence Chew, who has guided Prescient's clinical programs for the past 10 years. Dr. Lim brings over 20 years of experience in the pharmaceutical and biotechnology industries, with a strong background in clinical development and regulatory affairs. Dr. Lim will oversee the clinical development of Prescient's innovative pipeline, including its lead drug candidate PTX-100, which is currently beginning a Phase 2 study in Cutaneous T cell lymphoma (CTCL). Dr. Lim will also be responsible for advancing Prescient's next-generation cell therapy platforms, OmniCAR and CellPryme, which have the potential to transform CAR-T therapies. Dr. Lim previously held senior positions at Vifor Pharma, Ipsen and Telix, where she led the development and subsequent launch of several successful haematology and oncology therapies. She has also served as Clinical and Medical Advisor, as well as serving as the CMO to several biotechnology companies, providing expertise in clinical trial design, drug development, and regulatory strategy. Announcement • Mar 11
Prescient Therapeutics Limited Announces Board Changes, Effective 30 March 2025 Prescient Therapeutics Limited announced that Mr. Steven Engle has advised the Board that he will be retiring as Chair, and standing down from
the Board of Directors on 30 March 2025 after more than ten years in the role. The Board of Directors has elected current non-executive director Dr. James Campbell to succeed Mr. Engle as Chair. Dr. Campbell will assume the position on 30 March 2025. The Company is undertaking a search for a new non-executive director who can replace Dr. Campbell as Chair of the Audit and Risk Committee when he assumes the role of Board Chair on
30 March 2025. Board Change • Feb 04
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. Member of Scientific Advisory Board Donald O’Rourke was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Dec 24
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 9 highly experienced directors. Member of Scientific Advisory Board H. Prince was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Oct 14
Prescient Therapeutics Limited, Annual General Meeting, Nov 14, 2024 Prescient Therapeutics Limited, Annual General Meeting, Nov 14, 2024. Announcement • Jan 18
Prescient Therapeutics Limited Ordinary Shares to Be Deleted from OTC Equity Prescient Therapeutics Limited Ordinary Shares (Australia) will be deleted from OTC Equity effective January 18, 2024, due to Inactive Security. Board Change • Jan 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 9 highly experienced directors. Member of Scientific Advisory Board H. Prince was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. New Risk • Oct 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (12% increase in shares outstanding). Revenue is less than US$5m (AU$2.4m revenue, or US$1.5m). Market cap is less than US$100m (AU$50.7m market cap, or US$32.3m). Announcement • Oct 13
Prescient Therapeutics Limited, Annual General Meeting, Nov 16, 2023 Prescient Therapeutics Limited, Annual General Meeting, Nov 16, 2023, at 12:00 E. Australia Standard Time. Agenda: To receive and consider the financial report of the Company and the related reports of the Directors (including the Remuneration Report) and auditors for the year ended 30 June 2023; to consider the Adoption of Remuneration Report; to consider and Re-election of Dr Allen Ebens as a Director of the Company; to consider the Election of Dr Ellen Feigal as a Director of the Company; to consider the Ratification of Prior Issue of 1,415,000; and to consider the Approval of 10% Placement Facility. Board Change • Sep 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 6 highly experienced directors. Member of Scientific Advisory Board Phil Darcy was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • May 17
Prescient Therapeutics Limited Appoints Ellen Feigal to the Board as Non- Executive Director Prescient Therapeutics Limited announced the appointment of Dr. Ellen Feigal to the Board as a US-based independent, Non- Executive Director, effective 15 May 2023. Dr. Feigal brings a depth of experience in the commercialisation, product development and regulatory strategies in cell therapies, hematology and oncology. Her career spans leadership roles in industry, academia and nonprofits. Dr. Feigal is currently a Partner and Head of the Biologics practice at global life sciences advisory firm, NDA Partners LLC, where she leads efforts in designing and executing productdevelopment and regulatory strategies in the areas of cell therapies, medical imaging, hematology and oncology. She is also adjunct faculty at the Sandra Day O'Connor College of Law, Arizona State University, where she teaches FDA drug law and medical research ethics and law. Dr. Feigal was formerly Senior Vice President overseeing research and development with the California Institute of Regenerative Medicine, research foundation working to accelerate development of new disease modifying treatments and cures for patients with chronic diseases; Executive Medical Director, Global Development at US biotech company Amgen Inc.; Vice President of Clinical Sciences at the Translational Genomics Research Institute, and directed the Division of Cancer Treatment and Diagnosis at the National Cancer Institute. Dr Feigal serves as a Board member for Xencor Inc. a biotechnology company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases. She is also a Director of NextCure a clinical-stage biotechnology company developing new immunotherapies to treat cancer. Dr Feigal holds an M.D. from the University of California, Davis School of Medicine. She completed an internal medicine residency at Stanford University and a hematology oncologyfellowship at the University of California, San Francisco. 
